Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28233640.
- Also identified by DOI 10.1016/j.jcyt.2017.02.002 and PMC identifier 5410175.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Mesenchymal stromal cells (MSCs) are a type of adult stem cell that has been exploited for the treatment of a variety of diseases, including cancer. In particular, MSCs have been studied extensively for their ability to treat glioblastoma (GBM), the most common and deadly form of brain cancer in adults. MSCs are attractive therapeutics because they can be obtained relatively easily from patients, are capable of being expanded numerically in vitro, can be easily engineered and are inherently capable of homing to tumors, making them ideal vehicles for delivering biological antitumoral agents. Oncolytic viruses are promising biological therapeutic agents that have been used in the treatment of GBMs, and MSCs are currently being explored as a means of delivering these viruses. Here we review the role of MSCs in the treatment of GBMs, focusing on the intersection of MSCs and oncolytic viruses.
Medical subject headings
- Brain Neoplasms
- Glioma
- Mesenchymal Stem Cell Transplantation
- Mesenchymal Stem Cells
- Oncolytic Virotherapy
- Oncolytic Viruses